Tesamorelin

The short version

Why people discuss it

Egrifta WR is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Community discussion also focuses on abdominal fat and body recomposition outside that indication; those uses are not established by the label.

What it is

A growth hormone-releasing factor analog. Egrifta WR and Egrifta SV have different doses and preparation instructions and are not substitutable.

Biggest caution

Contraindications include active cancer, pregnancy, relevant pituitary-axis disruption and hypersensitivity. Long-term cardiovascular safety is not established; the full label covers monitoring and other risks.

Stack context

The approved indication does not establish a general fat-loss stack. No community combination is verified in this entry.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Sources report different amounts or schedules; the reference below is a named example, not a consensus.